Placebo Effect

• 

  Subject Areas on Research

  • A Novel Strategy to Identify Placebo Responders: Prediction Index of Clinical and Biological Markers in the EMBARC Trial. 
  • A comparison of placebo and no-treatment during a hypnotic clinical trial. 
  • A double-blind, placebo-controlled trial of four fixed rate infusion regimens of phenylephrine for hemodynamic support during spinal anesthesia for cesarean delivery. 
  • A randomized, controlled pilot study of acupuncture treatment for menopausal hot flashes. 
  • A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. 
  • A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies. 
  • Applications of TMS to therapy in psychiatry. 
  • Are the clinical effects of homoeopathy placebo effects? 
  • Central pain processing in irritable bowel syndrome is modulated by mood: a mechanism for the beneficial effects of antidepressants? 
  • Commercial features of placebo and therapeutic efficacy. 
  • Comparative "nocebo effects" in older patients enrolled in cancer therapeutic trials: Observations from a 446-patient cohort. 
  • Differential response to placebo among patients with social phobia, panic disorder, and obsessive-compulsive disorder. 
  • Don't ask, don't tell? Revealing placebo responses to research participants and patients. 
  • Dynamic nature of the placebo response. 
  • Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect. 
  • Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials. 
  • Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. 
  • Effectiveness of blinding: sham suprapubic incisions in a randomized trial of retropubic midurethral sling in women undergoing vaginal prolapse surgery. 
  • Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease. 
  • Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. 
  • Ethical considerations in design of a study to evaluate a US Food and Drug Administration-approved indication: antivenom versus placebo for copperhead envenomation. 
  • Expectancy Reduces Symptoms but not Functional Impairment Following Exercise-induced Musculoskeletal Injury. 
  • Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. 
  • Extended-release carbamazepine capsules as monotherapy in bipolar disorder : pooled results from two randomised, double-blind, placebo-controlled trials. 
  • From Bench to Bedside: Converting Placebo Research into Belief Activation. 
  • Healthy users, healthy adherers, and healthy behaviors? 
  • Improvement in the mechanical efficiency of walking: an explanation for the "placebo effect" seen during repeated exercise testing of patients with heart failure. Duke University Clinical Cardiology Studies (DUCCS) Exercise Group. 
  • Magnitude of placebo response and drug-placebo differences across psychiatric disorders. 
  • Meta-analysis of pain and function placebo responses in pharmacological osteoarthritis trials. 
  • Migraine therapeutics in adolescents: a systematic analysis and historic perspectives of triptan trials in adolescents. 
  • National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders. 
  • Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo. 
  • Placebo Response Rates in Trials of Licensed Drugs for Irritable Bowel Syndrome With Constipation or Diarrhea: Meta-analysis. 
  • Placebo Response and Practice Effects in Schizophrenia Cognition Trials. 
  • Placebo Response in Pediatric Anxiety Disorders: Results from the Child/Adolescent Anxiety Multimodal Study. 
  • Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review. 
  • Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disorders. 
  • Placebo response rate in clinical trials of fistulizing Crohn's disease: systematic review and meta-analysis. 
  • Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). 
  • Quantitative sensory testing in predicting persistent pain after joint replacement surgery: promise and challenges. 
  • Randomness, attributions of arousal, and belief in god. 
  • Redefined Measure of Early Neurological Improvement Shows Treatment Benefit of Alteplase Over Placebo. 
  • Response characteristics to antidepressants and placebo in post-traumatic stress disorder. 
  • Results of the FUEL Trial. 
  • Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I). 
  • Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery. 
  • Safety and efficacy of flecainide in subjects with Long QT-3 syndrome (DeltaKPQ mutation): a randomized, double-blind, placebo-controlled clinical trial. 
  • Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. 
  • Sample size requirements and length of study for testing interaction in a 2 x k factorial design when time-to-failure is the outcome [corrected]. 
  • Selecting methodologies for the evaluation of differences in time to response between antidepressants. 
  • The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease. 
  • The control group dilemma in clinical research: applications for psychosocial and behavioral medicine trials. 
  • The potential of a placebo/nocebo effect in pharmacogenetics. 
  • Unanticipated Insights into Biomedicine from the Study of Acupuncture. 
  • Viscoelastic testing to assess the effects of rapid fibrinogen concentrate administration after cardiopulmonary bypass: insights from the REPLACE study. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology